The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Adeosun urged Tinubu to redouble efforts at tackling the rising cost of drugs ... engagement of exited pharmaceutical companies to bring back investment in Research and Development (R&D) to ...

Opinion: Arnold & Porter's Mehrin "Mir" Masud-Elias questions the National Institute of Health's indirect cost cap, saying ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost ... of research and early product development, and the pharma partner ...

No matter how slow the current profit growth is, these companies spend on research and development (R&D ... continue to receive government support. Pharma companies truly deserve to be called ...

The main reason for this is that, somewhat unexpectedly, the Trump administration didn't impose tariffs on manufacturers of pharmaceutical ... vice president of research and development Jay ...

The U.S. pharmaceutical industry is bracing for a possible wave of tariffs on foreign-made drugs, even as they received a short-term exemption this week under President Donald Trump’s sweeping new ...